View bio, slides and more info: [ Ссылка ]
The types of therapeutics being studied to treat COVID-19 have changed. Chloroquine and azithromycin are out. Ibuprofen is ok. Remdesivir might still be in. A vaccine is on the horizon, be it made from RNA or inactivated fragments. In this webinar, Dr. Michael Chary, Instructor in Emergency Medicine at Weill Cornell Medical College, will discuss the most evidence-based therapeutics and review reasons why some earlier promising contenders faded out.
Speaker
Michael Chary, MD, PhD, Instructor in Emergency Medicine, Weill Cornell Medical College, New York, NY
Moderators
Paul M. Wax, MD, FACMT, Executive Director, American College of Medical Toxicology (ACMT)
Ziad Kazzi, MD, FACMT, Board Member, American College of Medical Toxicology (ACMT); President, Middle East & North Africa Clinical Toxicology Association (MENATOX)
This series is organized by the American College of Medical Toxicology (ACMT) supported by American Academy of Clinical Toxicology (AACT) | American Academy of Emergency Medicine (AAEM) | American Academy of Emergency Nurse Practitioners (AAENP) | American Association of Poison Control Centers (AAPCC) | Asia Pacific Association of Medical Toxicologists (APAMT) | Association of Healthcare Emergency Preparedness Professionals (AHEPP) | Emergency Nurses Association (ENA) | European Association of Poison Centers and Clinical Toxicologists (EAPCCT) | Middle East & North Africa Clinical Toxicology Association (MENATOX)
